NCT03752541: Allogeneic T-cells with Anti-BCMA CAR - BCMA-UCART in RRMM - Chinese study
Updated: May 28, 2022
NCT03752541: Efficacy and Safety Evaluation of BCMA-UCART
AllogeneicT-cells with Anti-BCMA CAR
Chimeric Antigen Receptor）in the Treatment of Relapsed or Refractory Multiple Myeloma
This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with relapsed or refractory multiple myeloma.
Sponsor
Bioray Laboratories
Collaborators
Shanghai Tongji Hospital, Tongji University School of Medicine
Second Xiangya Hospital of Central South University
ClinicalTrials.gov Identifier: NCT03752541
Efficacy and Safety Evaluation of BCMA-UCART（Allogeneic Engineered T-cells Expressing Anti-BCMA Chimeric Antigen Receptor）in the Treatment of Relapsed or Refractory Multiple Myeloma
First Posted : November 26, 2018
Click here for details on ClinicalTrials.gov
Biological: BCMA-UCART
Location
China, Shanghai
Shanghai Tongji Hospital